HMGB3 and ovarian cancer: A recent study demonstrated that the targeted depletion of HMGB3 sensitizes chemoresistant ovarian cancer cells to cisplatin through the inhibition of the ATR/CHK1/p-CHK1 DNA damage signaling pathway [22].